• miDiagnostics ultra-fast COVID-19 PCR Test succeeds in Brussels Airport pilot study

    Thursday February 17th 2022

  • Medical device Morphemat® wins Gold ‘Business Innovation’ Henry van de Velde Award

    Wednesday February 9th 2022

  • UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

    Friday February 4th 2022

  • Large UK study shows rapid EGFR testing with Idylla™ alongside NGS has potential to enhance lung cancer patient health outcomes

    Tuesday January 25th 2022

  • BIMZELX[®] (bimekizumab) approved in Japan for the treatment of plaque psoriasis, generalized pustular psoriasis and psoriatic erythroderma

    Monday January 24th 2022

  • argenx announces VYVGART™ approval in Japan for the treatment of generalized myasthenia gravis

    Friday January 21st 2022

  • argenx announces U.S. Food and Drug Administration (FDA) approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis

    Monday December 20th 2021

  • Early detection of Omicron facilitated with Emweb's Genome Detective

    Friday December 10th 2021

  • Your news here?

  • Biocartis’ Idylla™ SARS-CoV-2 testing successfully detects Omicron variant

    Thursday December 9th 2021

  • Spectacular results with Japanese encephalitis vaccine of ViroVet

    Wednesday December 8th 2021

  • New study demonstrates Idylla™ EGFR Mutation Test (CE-IVD) shortens time to patient management decisions for patients with non-small cell lung cancer

    Tuesday November 16th 2021

Strategic Partners